BiotechTube

E6007 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate Active Ulcerative Colitis

Conditions

Moderate Active Ulcerative Colitis

Trial Timeline

Nov 28, 2016 → Aug 16, 2019

NCT ID
NCT03018054

About E6007 + Placebo

E6007 + Placebo is a phase 2 stage product being developed by Eisai for Moderate Active Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03018054. Target conditions include Moderate Active Ulcerative Colitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03018054Phase 2Completed

Competing Products

20 competing products in Moderate Active Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
PexidartinibDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
Ranirestat + PlaceboEisaiPhase 2/3
65
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
85
KHK4827 + PlaceboKyowa KirinPhase 2
52
Stelara + Bmab1200BioconPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
77

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85